MDxHealth Announces Pricing of Offering of Ordinary Shares
MDxHealth Announces Pricing of Offering of Ordinary Shares
See original here:
MDxHealth Announces Pricing of Offering of Ordinary Shares
Author Archives: admin
Press Release: Availability of the Q3 2024 Aide mémoire
Availability of the Q3 2024 Aide mémoire
Read more from the original source:
Press Release: Availability of the Q3 2024 Aide mémoire
Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)
For media and investors only
More here:
Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
Read more here:
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
Alkeus Pharmaceuticals Announces Results from the SAGA Study of Oral Gildeuretinol in Patients with Geographic Atrophy Secondary to Age-Related…
CAMBRIDGE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that the SAGA study of oral gildeuretinol acetate (ALK-001) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) demonstrated a reduction of 0.25 sqmm/year vs. placebo (p=0.07) in the primary endpoint of GA lesion growth rate at 24 months. Gildeuretinol demonstrated a statistically significant reduction in the loss of low luminance visual acuity (LLVA) at 24 months (p=0.03). Gildeuretinol showed a favorable safety profile consistent with other studies of gildeuretinol in Stargardt disease. The topline results will be presented as a late breaker at the 128th Annual Meeting of the American Academy of Ophthalmology (AAO) during Retina Subspecialty Day on Friday, October 18, in Chicago.
Elicio Therapeutics Reports Inducement Grants
BOSTON, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on September 16, 2024, Elicio granted an aggregate of 4,800 inducement stock options to a new employee, as an inducement material to the individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio’s Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan.
See the article here:
Elicio Therapeutics Reports Inducement Grants
INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer’s Disease Trial Demonstrating Correlation between EMACC and…
BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, today announced that results of additional analysis of blinded data from its AD02 Phase II Alzheimer's Disease (AD) trial demonstrated exceptional performance of the novel cognitive measure EMACC, as well as highly significant correlation between EMACC and the Clinical Dementia Rating-Sum of Boxes (CDR-SB), the accepted endpoint for AD trials.
Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection
Assessment by specialist AI team from “PersonalAIze” Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform Assessment by specialist AI team from “PersonalAIze” Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform
Read more here:
Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection
Foxo Technologies, Inc., Completes the Acquisition of Revenue Generating Operations From Rennova Health, Inc.
Strategic Acquisitions Expected to Generate Over $20M in Annual Revenue, Positioning FOXO for Accelerated Growth Strategic Acquisitions Expected to Generate Over $20M in Annual Revenue, Positioning FOXO for Accelerated Growth
See the original post here:
Foxo Technologies, Inc., Completes the Acquisition of Revenue Generating Operations From Rennova Health, Inc.